

Declaration of Interests Register

TA Committee D

Publication Date: 14/10/2020

Topic: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (CDF Review of TA416)

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Matt Bradley	Committee Member	Financial interests	Holds shares in the company who makes the technology.	N/A	10/01/2020	N/A	It was agreed that this declaration would prevent Matt Bradley from participating in this section of the meeting.
Amanda Matse-Orere	Committee Member	Financial interests	Works for the manufacturer of EGFR tests.	N/A	22/01/2020	N/A	It was agreed that this declaration would prevent Amanda Matse-Orere from participating in this section of the meeting.
Shobhit Baijal	Clinical Expert	Financial interests	Received honorarium from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb, Chugai, Merck Serono, Novartis, Pierre Fabre, Pfizer, Roche (Pharma, Diagnostics, FoundationOne), Servier & Takeda for advisory boards.	N/A	06/02/2020	N/A	It was agreed that this declaration would not prevent Shobhit Baijal from participating in this section of the meeting.